The concept of MolecularMD grew out of discussions with Oregon Health Science University (OHSU) investigators, where the... Read More >   The singular purpose of MolecularMD is to provide the highest quality, most informative molecular diagnostic services for the diagnosis and monitoring of personalized medicine. Our current focus, in collaboration with recognized global leaders, is the development and commercialization of a world-class BCR-ABL RNA quantitation service for chronic myelogenous leukemia (CML) patients being treated by imatinib (GleevecŪ), bone marrow transplantation (BMT), and related therapeutics. To better serve a broader range of cancer patients, MolecularMD will expand our product offerings to include detection and quantitation of other cancer-related gene translocations. In addition we will be adding to our portfolio of gene mutation analyses.